Einarsdóttir Kristjana, Humphreys Keith, Bonnard Carine, Palmgren Juni, Iles Mark M, Sjölander Arvid, Li Yuqing, Chia Kee Seng, Liu Edison T, Hall Per, Liu Jianjun, Wedrén Sara
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
PLoS Med. 2006 Jun;3(6):e168. doi: 10.1371/journal.pmed.0030168. Epub 2006 May 9.
Checkpoint kinase 2 (CHEK2) averts cancer development by promoting cell cycle arrest and activating DNA repair in genetically damaged cells. Previous investigation has established a role for the CHEK2 gene in breast cancer aetiology, but studies have largely been limited to the rare 1100delC mutation. Whether common polymorphisms in this gene influence breast cancer risk remains unknown. In this study, we aimed to assess the importance of common CHEK2 variants on population risk for breast cancer by capturing the majority of diversity in the gene using haplotype tagging single nucleotide polymorphisms (tagSNPs).
We analyzed 14 common SNPs spanning 52 kilobases (kb) of the CHEK2 gene in 92 Swedish women. Coverage evaluation indicated that these typed SNPs would efficiently convey association signal also from untyped SNPs in the same region. Six of the 14 SNPs predicted well both the haplotypic and single SNP variations within CHEK2. We genotyped these six tagSNPs in 1,577 postmenopausal breast cancer cases and 1,513 population controls, but found no convincing association between any common CHEK2 haplotype and breast cancer risk. The 1100delC mutation was rare in our Swedish population--0.7% in cases and 0.4% in controls--with a corresponding odds ratio for carriers versus noncarriers of 2.26 (95% confidence interval, 0.99-5.15). Estimates of the population frequency and the odds ratio of 1100delC indicate that our sample is representative of a Northern European population.
Notwithstanding the involvement of the CHEK2 gene in breast cancer aetiology, we show that common polymorphisms do not influence postmenopausal breast cancer risk.
关卡激酶2(CHEK2)通过促进细胞周期停滞和激活基因受损细胞中的DNA修复来预防癌症发展。先前的研究已确定CHEK2基因在乳腺癌病因学中的作用,但研究主要限于罕见的1100delC突变。该基因的常见多态性是否影响乳腺癌风险仍不清楚。在本研究中,我们旨在通过使用单倍型标签单核苷酸多态性(tagSNP)捕获该基因中的大部分多样性,来评估CHEK2常见变异对人群乳腺癌风险的重要性。
我们分析了92名瑞典女性中CHEK2基因52千碱基(kb)范围内的14个常见单核苷酸多态性(SNP)。覆盖评估表明,这些分型的SNP也能有效地传递来自同一区域未分型SNP的关联信号。14个SNP中的6个能很好地预测CHEK2基因内的单倍型和单SNP变异。我们对这6个tagSNP在1577例绝经后乳腺癌病例和1513名人群对照中进行了基因分型,但未发现任何常见的CHEK2单倍型与乳腺癌风险之间有令人信服的关联。1100delC突变在我们的瑞典人群中很罕见——病例中为0.7%,对照中为0.4%——携带者与非携带者的相应比值比为2.26(95%置信区间,0.99 - 5.15)。1100delC的人群频率和比值比估计表明,我们的样本代表了北欧人群。
尽管CHEK2基因参与乳腺癌病因学,但我们发现常见多态性并不影响绝经后乳腺癌风险。